Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK highlights Cervarix's cross-protection in Phase III trial

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline's vaccine Cervarix has shown more than 90% efficacy in preventing cervical cancer caused by HPV 16 or 18 in young women previously uninfected with these virus types, and has also led to a substantial level of cross-protection against other key cancer-causing HPV types in its pivotal Phase III PATRICIA (HPV 008) trial.

You may also be interested in...



2011 Scrip 100: A new look at cancer chemoprevention

The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.

Janssen-Cilag's Xeplion recommended for EU approval for schizophrenia

Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.

Pfizer's Xiapex recommended for EU approval for Dupuytren's contracture

The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.

Topics

UsernamePublicRestriction

Register

LL065251

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel